Gilead Sciences, Inc. (GILD): Piling on the Phase 3 Data

Page 2 of 2

The true test will come when sofosbuvir is tested in combination with GS-5885 and ribavarin. If the all-oral regimen produces cure rates above 80%, it’ll have no problem competing with Incivek and Victrelis. Gilead will likely need higher cure rates than that, though, because other competitors are coming up from behind with their own all-oral regimen. AbbVie Inc (NYSE:ABBV)‘s  all-oral cocktail produced a 99% cure rate in its phase 2 trial and looked pretty good in patients who had failed to respond to previous treatments.

The article Piling on the Phase 3 Data originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2